This report provides an analysis of clinical trial racial representation data and evaluates racial demographics across a number of clinical trials sectors to highlight the level of diversity.
Analysis of Racial Representation across Multiple Clinical Trial Sectors
Analysis of Racial Representation across Multiple Clinical Trial Sectors
Scope
- The clinical trials data used for these analyses was extracted from the publisher's Clinical Trials Database, captured on June 16 and July 19, 2022. The data primarily includes clinical trials initiated from January 1, 2013 to June 16, 2022. Disclosed racial representation data has been analyzed by location, by year, phase, therapy area, sponsor type, top industry sponsors, pivotal study status, single country and multinational trials, decentralized trials, and CRO involvement. Additional analysis on obstacles in the recruitment of diverse subject populations in clinical trials and steps which can be taken to increase diversity have also been included.
Reasons to Buy
- Provides a breakdown of racial representation data across a number of clinical trial sectors.
- Identifies which areas are lacking in clinical trial population diversity.
- Highlights the variation in diversity in the industry and against institutional sponsors.
- Documents the barriers to diversity in clinical trials and outlines steps to improve it.
- Assesses how decentralized and virtual components in clinical trials affect diversity.
Table of Contents
- Executive Summary
- Introduction
- Analysis of Diversity in Clinical Trials (2013-2022)
- Key Findings
- Appendix
List of Figures
Figure 1: Percentage of clinical trials with disclosed racial representation data by region
Figure 2: Percentage of clinical trials with disclosed racial representation data in the top 10
- countries for clinical research
Figure 4: Racial representation in clinical trials by year
Figure 5: Proportional race representation in clinical trials by year
Figure 6: Racial demographic distribution by phase
Figure 7: Industry sponsors vs. institutional sponsors clinical trials racial representation
Figure 8: Racial representation in the top five therapy areas
Figure 9: Proportional racial representation of top company-sponsored trials
Figure 10: Racial representation in pivotal clinical trials
Figure 11: Racial representation of single country vs. multinational clinical trials
Figure 12: Racial representation of decentralized clinical trials vs. traditional trials
Figure 13: Racial representation of clinical trials with CRO involvement
Figure 14: Obstacles to clinical trial diversity
Figure 15: Increasing diversity in clinical trials
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Novartis
- GSK
- Pfizer
- Johnson & Johnson
- AstraZeneca
- F. Hoffmann-La Roche
- Eli Lilly
- Merck & Co
- AbbVie
- Bayer
